Effect of irbesartan,angiotensin 2 receptor antagonist(ARB)for urinary marker of the hypertensive patients

Effect of irbesartan,angiotensin 2 receptor antagonist(ARB)for urinary marker of the hypertensive patients - Effect of irbesartan,angiotensin 2 receptor antagonist(ARB)for urinary marker of the hypertensive patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011728

Enrollment

100

Registered

2013-09-12

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive patients

Interventions

When we give irbesartan 100 mg to hypertensive of the ARB or ACEI non-dosage and do not reach the aim blood pressure, we do dose increment to up to 200 mg. In the above, we gain weight and use CCB, a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hypertensive patients

Exclusion criteria

Exclusion criteria: 1;the patient of a serious impaired liver function (AST or ALT exceeds 3 times of a normal value maximum) 2;The patient that there is not serum K in a normal level range 3;A patient with pregnancy and breast-feeding or these schedules, and possibility 4;The patient who has an allergy anamnesis to a trial drug 5;the patient who judged that a doctor was unsuitable

Design outcomes

Primary

Measure	Time frame
Change of the marker in the urinary for 12 weeks,24weeks,and 48 weeks (urinary L-FABP,urinary NAG,urinary alfa 1-MG,urinary beta 2-MG;beta 2-microglobulin)	—

Countries

Japan

Contacts

Public ContactShogo kimura

JA Chuno Kousei Hospital Nephrology

shogo-k@kanazawa-med.ac.jp0575-22-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026